Revenue and Profit - Revenue for Q3 2025 reached ¥408,171,357.28, an increase of 19.45% year-over-year[5] - Net profit attributable to shareholders was ¥52,340,821.69, reflecting a growth of 16.83% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥50,943,889.79, up 14.98% year-over-year[5] - Total operating revenue for the current period reached ¥1,099,289,645.18, an increase of 10.4% compared to ¥996,169,384.90 in the previous period[21] - Net profit for the current period was ¥139,515,868.58, representing a growth of 10.7% from ¥125,968,441.87 in the previous period[22] - Earnings per share (EPS) for the current period was ¥0.2785, compared to ¥0.2363 in the previous period, reflecting a 17.8% increase[22] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥2,724,207,484.95, representing a 7.31% increase from the end of the previous year[5] - Total assets amounted to ¥2,724,207,484.95, up from ¥2,538,704,154.72 in the previous period, indicating a growth of 7.3%[20] - Total liabilities increased to ¥684,849,202.09, compared to ¥600,352,967.81 in the previous period, marking a rise of 14.1%[20] - The total equity attributable to shareholders of the parent company was ¥1,924,404,632.22, up from ¥1,818,146,758.50, reflecting a growth of 5.8%[20] Cash Flow - Cash flow from operating activities showed a significant decline, with a net amount of ¥49,269,616.14, down 70.31% year-to-date[5] - Operating cash inflow for the current period was CNY 1,071,546,121.46, a decrease of 7.15% compared to CNY 1,154,237,831.53 in the previous period[23] - Net cash flow from operating activities was CNY 49,269,616.14, down 70.34% from CNY 165,931,004.75 in the previous period[23] - Cash outflow from investment activities totaled CNY 61,629,478.26, compared to CNY 69,475,798.50 in the previous period, indicating a decrease of 11.67%[23] - Net cash flow from investment activities was -CNY 38,534,318.42, an improvement from -CNY 69,300,330.01 in the previous period[23] - Cash inflow from financing activities was CNY 2,651,100.53, an increase from CNY 1,179,642.55 in the previous period[24] - Net cash flow from financing activities was -CNY 37,742,850.79, slightly improved from -CNY 39,397,150.56 in the previous period[24] - The cash and cash equivalents at the end of the period amounted to CNY 808,754,546.46, up from CNY 796,228,461.84 in the previous period[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 37,268[13] - The largest shareholder, Beijing Yizhuang Investment Holding Co., Ltd., holds 29.57% of shares, totaling 152,997,984 shares[13] - The total number of shares held by the top ten unrestricted shareholders includes 73,985,522 shares held by Macaud Holdings Limited, accounting for 14.30%[13] - The company reported a total of 2,041,800 restricted shares at the end of the period, with no new restrictions added[15] - The company has no preferred shareholders or changes in preferred shares during the reporting period[14] Expenses and Impairments - Financial expenses increased by 30.62% to -¥2,596,000, primarily due to exchange rate impacts[9] - The company experienced a 331.29% increase in credit impairment losses, totaling -¥2,496,000, due to higher provisions for bad debts[9] - Research and development expenses for the current period were ¥60,434,000.05, an increase from ¥55,419,207.71 in the previous period, showing a growth of 9.1%[21] - The company reported a credit impairment loss of ¥-24,962,478.43, worsening from ¥-5,787,820.05 in the previous period[21] Other Financial Metrics - The weighted average return on equity was 2.88%, an increase of 0.34% compared to the previous year[5] - Other comprehensive income after tax for the current period was ¥-3,182,736.95, compared to ¥-4,325,724.98 in the previous period, indicating an improvement[22] - The company received CNY 21,977,927.92 in tax refunds, an increase from CNY 15,262,292.02 in the previous period[23] - The company paid CNY 158,556,720.56 in other operating cash outflows, down from CNY 239,015,992.90 in the previous period, a decrease of 33.67%[23] - The company reported a cash flow impact from foreign exchange fluctuations of CNY 12,787,550.65, compared to -CNY 5,302,823.56 in the previous period[24]

Core Viewpoint - 麦克奥迪's stock has shown a mixed performance with a recent decline, while the company continues to report growth in revenue and net profit year-over-year [1][2]. Financial Performance - As of June 30, 麦克奥迪 achieved a revenue of 6.91 billion, representing a year-over-year growth of 5.60% [2]. - The net profit attributable to shareholders for the same period was 917.75 million, reflecting an 18.46% increase compared to the previous year [2]. Stock Performance - 麦克奥迪's stock price decreased by 2.02% to 18.91 yuan per share, with a trading volume of 3.01 billion and a turnover rate of 3.06% [1]. - Year-to-date, the stock has increased by 8.43%, with a 4.94% rise over the last five trading days, 7.08% over the last twenty days, and 20.52% over the last sixty days [1]. Shareholder Information - As of June 30, 麦克奥迪 had 37,200 shareholders, an increase of 4.09% from the previous period, with an average of 13,840 circulating shares per shareholder, down by 3.93% [2]. - The company has distributed a total of 3.47 billion in dividends since its A-share listing, with 1.29 billion distributed over the last three years [3]. Major Shareholders - The sixth-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 2.46 million shares, an increase of 470,100 shares from the previous period [3]. - 华夏行业景气混合A (003567) is a new shareholder, holding 2.45 million shares [3]. Business Overview - 麦克奥迪 specializes in medical, optoelectronic, and smart electrical businesses, with revenue contributions of 60.06% from electrical products, 25.64% from microscopes, and 14.30% from medical products and services [1].

麦克奥迪（厦门）电气股份有限公司 关于公司股东权益变动触及1%整数倍的提示性公告 本公司股东嘉兴嘉逸投资合伙企业（有限合伙）保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 麦克奥迪（厦门）电气股份有限公司（以下简称"公司"）于 2025 年 7 月 30 日在中国证监会指定的创业板信息披露网站巨潮资讯网（www.cninfo.com.cn） 披露了《关于公司股东减持股份预披露公告》。公司股东嘉兴嘉逸投资合伙企业 （有限合伙）计划在上述减持计划预披露公告披露之日起 15 个交易日后的三个 月内以集中竞价方式减持本公司股份 5,174,100 股，占本公司总股本比例 1%。 公司收到了股东嘉兴嘉逸投资合伙企业（有限合伙）出具的《关于权益变动 触及 1%整数倍的告知函》。嘉兴嘉逸投资合伙企业（有限合伙）通过集中竞价交 易方式减持公司无限售条件流通股 2,649,500 股。本次权益变动后，嘉兴嘉逸投 资合伙企业（有限合伙）持有公司股份 22,858,670 股，占公司总股本的比例为 4.42%；与一致行动人嘉 ...

Group 1 - The core viewpoint of the news is that 麦克奥迪 (Xiamen McAudie Electric Co., Ltd.) has seen a stock price increase of 6.23%, reaching 19.96 CNY per share, with a trading volume of 575 million CNY and a turnover rate of 5.89%, resulting in a total market capitalization of 10.328 billion CNY [1] - 麦克奥迪 was established on November 4, 2002, and went public on July 26, 2012. The company's main business segments include "medical business," "optoelectronic business," and "smart electrical business" [1] - The revenue composition of 麦克奥迪 is as follows: electrical products account for 60.06%, microscopes account for 25.64%, and medical products and services account for 14.30% [1] Group 2 - 华夏行业景气混合 (Huaxia Industry Prosperity Mixed Fund) has entered the top ten circulating shareholders of 麦克奥迪, holding 2.4513 million shares, which is 0.48% of the circulating shares. The estimated floating profit today is approximately 2.868 million CNY [2] - The fund was established on February 4, 2017, with a latest scale of 7.261 billion CNY. Year-to-date returns are 59.33%, ranking 665 out of 8173 in its category; the one-year return is 105.64%, ranking 433 out of 8003; and since inception, the return is 389% [2] Group 3 - The fund manager of 华夏行业景气混合 is 钟帅, who has been in the position for 5 years and 61 days. The total asset scale of the fund is 8.253 billion CNY, with the best fund return during his tenure being 181.19% and the worst being 14.47% [3]

Group 1 - The core viewpoint of the news is that 麦克奥迪 (Xiamen McAudie Electric Co., Ltd.) has seen a significant stock price increase of 6.23%, reaching 19.96 CNY per share, with a trading volume of 577 million CNY and a turnover rate of 5.91%, resulting in a total market capitalization of 10.328 billion CNY [1] - 麦克奥迪 was established on November 4, 2002, and went public on July 26, 2012. The company operates in three main business segments: medical business, optoelectronic business, and smart electrical business [1] - The revenue composition of 麦克奥迪 is as follows: electrical products account for 60.06%, microscopes for 25.64%, and medical products and services for 14.30% [1] Group 2 - From the perspective of fund holdings, one fund under 鑫元基金 (Xinyuan Fund) has a significant position in 麦克奥迪. The fund, 鑫元国证2000指数增强A (018579), held 74,200 shares in the second quarter, representing 0.92% of the fund's net value, making it the sixth-largest holding [2] - The fund has achieved a year-to-date return of 35.35%, ranking 1449 out of 4220 in its category, and a one-year return of 74.85%, ranking 1034 out of 3820 [2] - The fund manager, 刘宇涛 (Liu Yutao), has been in charge for 3 years and 7 days, with a total asset scale of 554 million CNY. The best return during his tenure is 34.06%, while the worst is -0.31% [2]

Core Insights - The 22nd China-ASEAN Expo was held in Nanning, Guangxi, where the gastric cancer pathology diagnostic model V1 was officially launched, marking a breakthrough in the application of artificial intelligence in medical pathology [1][2] - The collaboration between MacAudie and Beijing Yizhuang Intelligent City Research Institute Group represents an innovative practice of cross-industry integration between healthcare and technology [1] Company Overview - MacAudie has three core business segments: intelligent electrical, smart optics, and digital healthcare, showcasing its deep accumulation and development blueprint in energy management, optical innovation, and the full value chain of digital pathology [1] - The gastric cancer pathology diagnostic model V1 consists of two main functional modules: the negative screening model and the classification model, aimed at reducing the workload of pathologists by up to 80% and enhancing diagnostic focus and efficiency [2] Industry Impact - The negative screening model significantly reduces repetitive tasks for pathologists by accurately identifying normal or non-cancerous pathology samples, while the classification model addresses the challenge of precision in identifying common gastric cancer types [2] - This innovation alleviates the shortage of pathology experts and promotes a shift from experience-driven to intelligence-enabled pathology diagnostics [2] Future Developments - The collaboration will continue to focus on the full-process diagnostic needs for gastric cancer, with plans to develop automated diagnostic report generation and ROI intelligent recognition features [3] - The goal is to enhance the model's functionality and expand its application to more tumors and pathology scenarios, contributing to the Healthy China 2030 strategic goal [3]

Group 1 - The core viewpoint is that 麦克奥迪实业集团有限公司 has obtained a patent for an "Electric Turntable and Optical Microscope," which is significant in the field of optical imaging technology [1] - The patent includes components such as a base, turntable, motor, gears, magnets, and sensors, indicating a complex design aimed at enhancing optical imaging capabilities [1] - The application date for the patent is November 2024, suggesting future developments in the company's product offerings [1] Group 2 - 麦克奥迪实业集团有限公司 was established in 1995 and is located in Xiamen, primarily engaged in the manufacturing of instruments and meters [2] - The company has a registered capital of 172.1941 million RMB and has made investments in 13 enterprises, indicating a diversified business strategy [2] - 麦克奥迪 has participated in 626 bidding projects and holds 378 patents, showcasing its active role in innovation and market competition [2]

Group 1 - Weisheng Information won four projects in August with a total amount of 85.5377 million yuan, accounting for 3.12% of the company's total revenue for 2024 [1] - Longqi Technology's shareholder plans to reduce its stake by up to 4.09%, equating to a maximum of 19.1916 million shares [1] - Guojin Modern's subsidiary received a drug registration certificate for injectable Nicardipine, used for treating unstable angina [3][4] Group 2 - SAIC Motor reported a total vehicle sales of 363,400 units in August, a year-on-year increase of 41.04%, with new energy vehicle sales reaching 129,800 units, up 49.89% [5] - Kuka Home plans to invest 1.124 billion yuan to build a self-owned base in Indonesia, aiming to enhance its international strategy [6] - Samsung Medical's subsidiary signed a contract for an intelligent meter project in Egypt worth 58.8 million USD, approximately 419 million yuan [8] Group 3 - North Vehicle Blue Valley's subsidiary reported a total production of 10,587 units in August, a year-on-year decrease of 15.13%, while sales increased by 3.47% [12] - Xianghe Industrial signed contracts worth 400 million yuan for railway fastener system components [13] - Hengrui Medicine's HRS9531 injection has received acceptance for its marketing authorization application [14] Group 4 - Hualu Hengsheng resumed normal production after completing maintenance on production facilities [16] - Shanghai Pharmaceuticals' hydrochloride verapamil injection passed the consistency evaluation for generic drugs [18] - Shanghai Construction received approval for debt financing tools with a registration period of two years [20] Group 5 - Kangli Elevator terminated the sale of its wholly-owned subsidiary due to the buyer's failure to obtain necessary approvals [21] - Times Wan Heng appointed Li Zhizhong as the new deputy general manager [22] - Hanma Technology reported a total truck sales of 1,051 units in August, a year-on-year increase of 58.05% [24] Group 6 - Wenzhou Hongfeng's subsidiary received a utility model patent certificate for a servo adjustment device [26] - Yibin Technology received a project designation from a domestic new energy vehicle company, with an estimated total sales of 243 million yuan over five years [28] - Star Ring Technology's H-share issuance application was accepted by the China Securities Regulatory Commission [30] Group 7 - Microchip Bio's vice president resigned for personal reasons [31] - Zhongxin Co. announced the resignation of a non-independent director due to personal reasons [32] - Changcheng Military Industry's vice chairman resigned due to retirement [35] Group 8 - Jiukang Bio received four invention patent certificates related to detection reagents [36] - Meino Bio's subsidiary changed its registered address [37] - Kuangda Technology announced a potential change in control due to a share transfer [38] Group 9 - China Rare Earth confirmed no undisclosed significant matters amid stock price fluctuations [72]

Mergers and Acquisitions - Huahong Company plans to acquire 97.5% equity of Huali Microelectronics through a combination of issuing shares and cash payment, raising supporting funds [1] - Olin Bio intends to acquire 15% equity of Xinnuo Ming Bio from minority shareholders via public transfer at a price not exceeding 45 million yuan [2] - Dongxin Co. plans to invest approximately 211 million yuan in Shanghai Lishuan, holding about 35.87% equity post-investment [3] Shareholding Changes - Gao Neng Environment's controlling shareholder plans to reduce holdings by up to 3%, equating to a maximum cash-out of 320 million yuan [4][5] - Hu Dian Co.'s senior management intends to reduce holdings by up to 16,040 shares, representing about 0.0083% of total equity [6] - Maike Audi's shareholders have collectively reduced their holdings by 2.17%, with specific reductions of 5.41 million shares and 5.86 million shares [7] Risk Matters - *ST Tianmao plans to voluntarily withdraw its A-share listing and will initiate a protection mechanism for dissenting shareholders [8] - China Rare Earth confirms no undisclosed matters that could affect stock trading prices amid unusual trading fluctuations [9] Lock-up Release - Suda Co. announces that approximately 27.94 million shares will be released from lock-up on September 3, 2025, accounting for 36.76% of total equity [10]

Mergers and Acquisitions - Huahong Company plans to acquire 97.5% equity of Huali Microelectronics through a combination of issuing shares and cash payment, with the stock resuming trading on September 1, 2025 [1] - Olin Bio intends to acquire 15% equity of Xinnuo Ming Bio from minority shareholders through a public transfer at a price not exceeding 4.5 million yuan, with a potential increase of up to 5% from the base price [2] - Dongxin Co. plans to invest approximately 211 million yuan in Shanghai Lishuan, holding about 35.87% equity post-investment, as part of a total investment of around 500 million yuan [3] Shareholding Changes - Gaon Environment's controlling shareholder plans to reduce holdings by up to 3%, amounting to no more than 45.697 million shares [4] - Hushen Co.'s senior executive intends to reduce holdings by up to 160,400 shares, representing approximately 0.0083% of the total share capital [5] - Macao Di's shareholders have collectively reduced their holdings by 2.17%, with one shareholder reducing approximately 5.41 million shares and another reducing about 5.86 million shares [6] Risk Matters - *ST Tianmao plans to voluntarily withdraw its A-share listing on the Shenzhen Stock Exchange and will initiate a protection mechanism for dissenting shareholders, offering cash options to certain shareholders [7] - China Rare Earth confirms no undisclosed matters that should be reported, despite unusual trading fluctuations [8][9] Lock-up Release - Suda Co. announces that approximately 27.937 million shares, accounting for 36.76% of the total share capital, will be released from lock-up on September 3, 2025 [10]